ArticleInfection2026
Title of the article: Aeromonas infections in humans: clinical presentation, resistance patterns, and outcomes in a south indian tertiary care centre.
Article in Infection, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAeromonas species are increasingly recognized as emerging human pathogens capable of causing a wide spectrum of infections ranging from skin and soft tissue infections to life-threatening bacteremia. Data from India describing their clinical spectrum and antimicrobial resistance patterns remain limited.
methodsWe conducted a retrospective study of 61 culture-proven cases of Aeromonas infection identified between 2019 and 2025 at a tertiary care centre in South India. Demographic characteristics, clinical presentation, comorbidities, microbiological findings, antimicrobial susceptibility patterns, treatment, and outcomes were analysed.
resultsThe mean patient age was 46 years, and 57% were male. The most common clinical presentations were skin and soft tissue infections (40.9%) and bacteremia (40.9%), while pulmonary and urinary infections were less frequent. Common comorbidities included diabetes mellitus (27.8%) and chronic liver disease (14.7%), and trauma preceded infection in 16.3% of cases. Antimicrobial susceptibility testing showed high resistance to carbapenems, with resistance rates of 54.7% to meropenem and 27.8% to imipenem. In contrast, cephalosporins largely retained activity. Overall, 81.9% of patients recovered, whereas the mortality rate was 13.1%
conclusionAeromonas infections present with diverse clinical manifestations and may show substantial resistance to carbapenems. Early microbiological diagnosis and rational antibiotic selection are essential for optimal management and improved outcomes.
Indexed as
Identifiers
41801636What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.